Scrip
ViiV's Selzentry approved for treatment-naive HIV patients in US
24 November 2009
Katie McQue
Please Login to read the full article.
24 November 2009
Katie McQue
katie.mcque@informa.com
The US FDA has approved a label expansion of ViiV Healthcare's CCR5 antagonist Selzentry (maraviroc) to include treatment-naive HIV patients.
The move follows an endorsement last month by an FDA advisory panel for use of the drug in this patient population.
The label expansion also...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Tobira's CCR5 antagonist passes Phase IIa HIV trial
- Shionogi/ViiV's HIV integrase inhibitor set for Phase III trials
- J&J's HIV drug rilpivirine passes Phase III trials but stumbles on virologic failure
- Dual Kaletra/Isentress HIV regimen looks as effective as traditional HAART
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
